GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (NSE:LUPIN) » Definitions » Gross-Profit-to-Asset %

Lupin (NSE:LUPIN) Gross-Profit-to-Asset % : 55.36% (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lupin Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Lupin's annualized Gross Profit for the quarter that ended in Mar. 2024 was ₹132,851 Mil. Lupin's average Total Assets over the quarter that ended in Mar. 2024 was ₹239,972 Mil. Therefore, Lupin's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 55.36%.


Lupin Gross-Profit-to-Asset % Historical Data

The historical data trend for Lupin's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Gross-Profit-to-Asset % Chart

Lupin Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.65 37.08 40.08 42.39 55.43

Lupin Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.96 54.04 55.22 57.22 55.36

Competitive Comparison of Lupin's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lupin's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lupin's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Lupin's Gross-Profit-to-Asset % falls into.



Lupin Gross-Profit-to-Asset % Calculation

Lupin's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=130128.7/( (229559.3+239971.8)/ 2 )
=130128.7/234765.55
=55.43 %

Lupin's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=132850.8/( (0+239971.8)/ 1 )
=132850.8/239971.8
=55.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Lupin Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Lupin's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lupin (NSE:LUPIN) Business Description

Traded in Other Exchanges
Address
Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400 055
Lupin Ltd is a specialty and generic drug manufacturing company. The company's global formulations business develops and delivers a wide range of branded and generic formulations across the globe. The operations of the company are limited to one segment, namely pharmaceuticals and related products. The company also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India.

Lupin (NSE:LUPIN) Headlines

No Headlines